Zavzpret (zavegepant nasal spray) / Pfizer - LARVOL DELTA

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study. (PubMed, Pain Ther) - P2/3 | "Through the 52-week study, acute treatment with zavegepant was associated with reduction in mean number of migraine days/month, improvements in migraine-related disability and migraine-specific quality of life, and high levels of patient satisfaction."

Journal • CNS Disorders • Migraine • Pain

Gepants: targeting the CGRP pathway for migraine relief. (PubMed, Front Pharmacol) - "Several new agents (atogepant, ubrogepant, rimegepant, and zavegepant) expand therapeutic options beyond traditional triptans and monoclonal antibodies. Gepants represent a valuable advancement in migraine therapy, offering effective acute and preventive options with favorable tolerability, particularly for patients who cannot use triptans or who have cardiovascular risk factors. Ongoing studies will clarify long-term safety, real-world effectiveness, and potential roles in combination or sequential therapy."

Journal • Review • Cardiovascular • CNS Disorders • Fatigue • Migraine • Pain

Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care. (PubMed, Am J Manag Care) - "Ubrogepant, rimegepant, and zavegepant are not cost-effective options for acute migraine treatment but may be appropriate for patients experiencing 2 or fewer migraines per month. If a gepant is to be prescribed, rimegepant is the most cost-effective option of the 3."

Clinical • HEOR • Journal • CNS Disorders • Migraine • Pain

Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care (AJMC) - "None of the gepants were cost-effective at willingness-to-pay thresholds of $50,000, $100,000, or $150,000 per QALY. Among the 3 gepants, rimegepant was the most cost-effective option; it had an incremental cost-effectiveness ratio of $93,700.20 per QALY compared with ubrogepant and was both less costly and more effective than zavegepant."

HEOR • Migraine

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults. (PubMed, Clin Pharmacol Drug Dev) - "Results were comparable to exposures observed previously in non-Asian healthy participants following a single intranasal dose of zavegepant 10 mg. Zavegepant demonstrated a favorable safety profile, with no serious or severe adverse events and no clinically relevant findings regarding laboratory tests, vital signs, or electrocardiograms observed."

Journal • P1 data • PK/PD data • CNS Disorders • Migraine • Pain

Early Experience Treating Vestibular Migraine with Small Molecule CGRP Antagonists (AAO-HNSF 2025) - "The gepants used included ubrogepant, rimegepant, atogepant, and zavegepant. Gepants can be effective medications for the treatment of vestibular migraine."

CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo

KNOWLEDGE DISCOVERY IN DATASETS: DRUGGABLE TARGETS FOR PANCREATIC DUCTAL ADENOCARCINOMA (UEGW 2025) - "Of note, EIF2A had high affinity to Padnarsertib (orally small molecular drug) with -11.4 kcal/mol, whereas STAMBP had affinity to Bemcentinib (orally small molecular drugs) with -11.8 kcal/mol, and ANXA2 and AHNAK2 to Zavegepant (CGRP receptor antagonist as migraine drug) with -12.1 kcal/mol and -11.4 kcal/mol, respectively, suggesting druggable targets on endocytosis/exocytosis/phagocytosis and CGRP signaling pathways. Potential druggable targets for PDAC were identified by KDD, particularly including the key proteins with repurposed drugs acting on the ERK/MAPK signaling pathway (involved CGRP) and the membrane fusion."

CNS Disorders • Migraine • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • ACADSB • AHNAK2 • ANXA2 • ANXA3 • EIF2A • EIF2S1 • MYH14 • POLR2H • SPTAN1 • VIL1

TrumpRx unveiled with up to 85% discount on four Pfizer drugs (SeekingAlpha) - "The White House on Tuesday announced the launch of a direct-to-consumer website called TrumpRx, through which Pfizer (NYSE:PFE) has agreed to sell four of its prescription medicines, including its blockbuster arthritis drug Xeljanz, at up to an 85% discount. In addition to Xeljanz, which will be available at a 40% discount, the New York-based company has agreed to offer discounts ranging from 50% to 85% for its dermatitis drug Eucrisa, osteoporosis therapy Duavee, and migraine therapy Zavzpret."

Commercial • Ankylosing Spondylitis • Atopic Dermatitis • Idiopathic Arthritis • Migraine • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Quantifying Placebo Response in Randomized Phase 2 and 3 Trials of Anti-CGRP Targeting Therapies for the Acute Treatment of Migraine: A Systematic Review and Meta-Analysis (IHC 2025) - "Subgroup analysis by drug type showed response rates of 47.5% for rimegepant, 51.4% for zavegepant, and 48.1% for ubrogepant. Limitations in the number and heterogeneity of trials by site, intervention assignment, and phase restricted further analysis. Further high-quality RCTs are needed to better assess contextual contributors to placebo response."

P2 data • Retrospective data • Review • CNS Disorders • Migraine

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo-controlled trials. (PubMed, Headache) - "In healthy adults, zavegepant nasal spray was safe and well tolerated at single dose up to 40 mg and in multiple doses up to 40 mg QD. Zavegepant median Tmax was approximately 30 min after a single 10 mg dose nasal spray."

Clinical • Journal • P1 data • PK/PD data • CNS Disorders • Hepatology • Liver Failure • Migraine • Pain

Real-World Data Highlight Patient-Reported Benefits of Intranasal Zavegepant for Acute Migraine (NeurologyLive) - "In a real-world study conducted at the Cleveland Clinic, patients using 10-mg intranasal zavegepant (Zavzpret; Pfizer) for acute migraine reported meaningful pain relief, improved daily functioning, and high willingness to reuse the therapy through the validated migraine treatment optimization questionnaire-5 (MTOQ-5)....Presented at the 2025 American Headache Society (AHS) Annual Meeting, lead author Eric Dunn, DO, a neurologist at Cleveland Clinic, and colleagues evaluated patient-reported outcomes of individuals using 10-mg intranasal zavegepant for acute migraine treatment. Overall, the drug exemplified encouraging results, including benefits on pain relief, functional improvement, and a high willingness to reuse....As for acute efficacy, 45.0% of patients reported achieving complete pain relief within 2 hours of treatment at least half the time, 28.3% reported this benefit less than half the time, and 26.7% never achieved pain relief within that timeframe."

Real-world • Real-world evidence • Migraine

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. (PubMed, J Headache Pain) - "The present pharmacovigilance study systematically revealed the significant risk signals of gepants. The common AEs and unique AEs of the four gepants were also identified and explored. Our results would provide valuable reference for the safe use of gepants, guiding personalized drug selection in clinical practice."

Adverse events • Journal • CNS Disorders • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022 (AHS 2025) - "Following migraine QOC indicators selected based on current literature were assessed among diagnosed migraine patients: (1) migraine-related healthcare visits: emergency department (ED), urgent care, neurology, primary care, outpatient, inpatient hospitalizations in each full calendar year, and 30-day hospital readmission following the first hospitalization; (2) medication use: acute (generic [triptans, opioids, NSAIDs, ergotamines, barbiturates, and acetaminophen] and branded [Ubrogepant, Zavegepant, Lasmiditan, Rimegepant (when the first prescription is for less or equal to 8 pills)]) and preventive (oral migraine preventive medications[OMPM; anticonvulsants, antidepressants, antihypertensives, and other oral combination medications] and branded [CGRP mAbs, Botox, Atogepant, Rimegepant (when the first prescription is for >8 pills)]) migraine treatments; (3) other migraine-related diagnoses: acute medication overuse (AMO) based on medication utilization algorithm and..."

Clinical • CNS Disorders • Migraine • Pain

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women (AHS 2025) - "A single intranasal dose of 10 mg zavegepant is generally safe and well tolerated in healthy lactating women and the estimated infant exposure to zavegepant via breast milk is very low."

Clinical • P1 data • PK/PD data • CNS Disorders • Migraine • Pain

Long-term safety and tolerability of zavegepant 10 mg nasal spray by dosing frequency: Post-hoc analysis of a phase 2/3 open-label study (AHS 2025) - P2/3 | "Zavegepant displayed a similar safety profile in individuals with migraine who administered <2, 2 to <4, or ≥4 sprays/month over a period of 52 weeks, with a majority in each subgroup reporting a reduction in mean MMDs."

Clinical • P2/3 data • Retrospective data • Back Pain • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

Real-world outcomes of zavegepant use in a tertiary care setting using migraine treatment optimization questionnaire-5 (MTOQ-5) (AHS 2025) - "Although a phase 3 clinical trial demonstrated the efficacy, favorable tolerability, and safety of zavegepant, further investigations are necessary to establish its long-term safety and consistency of effect. This study represents the first retrospective, real-world patient-reported outcome study on the use of zavegepant using the validated MTOQ-5. Our data implies that zavegepant is a strong option among the CGRP class for acute therapy with a quick onset of efficacy and improvement in pain and MBS."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient-Centric Microsampling. (PubMed, Clin Transl Sci) - P1 | "For Tasso-Plus versus venous phlebotomy, 39 of 41 (95.1%) data pairs met concentration correlation criteria (difference within 20% of the mean), median zavegepant concentration-time profiles were comparable, and 90% confidence intervals for geometric mean ratios for AUClast and Cmax were wholly within the range of bioequivalence acceptance (80%-125%). The results of this study confirm that it is feasible to use serum derived from Tasso-Plus collection of whole capillary blood as a reliable PCS approach for PK analysis of zavegepant."

Journal • PK/PD data

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults (clinicaltrials.gov) - P3 | N=1414 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Migraine • Pain

Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. (PubMed, J Headache Pain) - No abstract available

Journal • Review • CNS Disorders • Migraine • Pain

Clinical evaluation of zavegepant for the acute treatment of migraine. (PubMed, J Manag Care Spec Pharm) - "This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their zavegepant product review in March 2024."

Journal • Review • CNS Disorders • Migraine • Pain

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • CNS Disorders • Migraine • Pain

Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study. (PubMed, Headache) - "Self-administration of ZAV 10-mg nasal spray for the acute treatment of migraine up to 8 times/month for up to 52 weeks appeared well-tolerated irrespective of concomitant use of CGRP mAbs or OSPs."

Journal • P2/3 data • Back Pain • Cardiovascular • CNS Disorders • Infectious Disease • Migraine • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Cost-effectiveness Analysis of Zavegepant in Acute Migraine Treatment (ISPOR 2025) - "Zavegepant is cost-effective compared with rimegepant for the acute treatment of migraine under the threshold of $100,000 per QALY gained."

Cost effectiveness • HEOR • CNS Disorders • Migraine • Pain

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. (PubMed, Pain Manag) - "The NNT values for achieving pain freedom at two hours were 9 for rimegepant, 11 for zavegepant, and 12 for ubrogepant, which are comparable to NSAIDs such as naproxen (NNT = 11). Triptans demonstrated lower NNTs, indicating higher efficacy. Gepants offer effective, well-tolerated alternatives with no significant cardiovascular risk and minimal potential for medication-overuse headache."

Head-to-Head • Journal • Review • Cardiovascular • CNS Disorders • Migraine • Pain